DOWNLOADABLE RESOURCES
Explore the following resources to learn more about recent developments in the treatment of ES-SCLC.
ASTRUM-005 PUBLICATION
ASTRIDE TRIAL IN-PROGRESS POSTER
Astrum-005 Extended Follow Up Results
ES-SCLC=extensive-stage small-cell lung cancer.
ABOUT FOSUN PHARMA
Fosun Pharma USA Inc. was established in 2017, with headquarters in Princeton, New Jersey. Fosun Pharma USA Inc. is a wholly owned subsidiary of Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun HQ”). Fosun HQ, founded in 1994 and headquartered in Shanghai, is a top global, innovation-driven pharmaceutical and healthcare industry group.
As a U.S.-focused specialty pharmaceutical company, Fosun Pharma USA:
- Innovates through strategic partnerships and building its commercial presence in the United States
- Advances innovative products to patients in need by leveraging its global parent company, Fosun Pharma Group, as well as a unique R&D model
- Is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D
- Maintains a portfolio comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high-value, branded innovative products
Fosun Pharma USA continues to build its pipeline with late development stage (phase 2 and beyond) or commercial stage innovative products dedicated to the U.S. market. While Fosun Pharma USA can facilitate a partnership with Fosun HQ for the Chinese market, the focus is on U.S. rights for innovative biopharmaceutical products. Website: www.fosunpharmausa.com; Follow us on LinkedIn for more company updates: Fosun Pharma USA Inc.